한글목차

세계 임상시험 용품 시장 규모는 2025년 53억 4,000만 달러에서 2030년 81억 8,000만 달러에 이르고, 연평균 8.9%의 높은 성장률을 나타낼 것으로 예상됩니다.

임상시험 용품 시장은 전 세계 임상시험의 양과 복잡성 증가, 개인 맞춤형 의료의 부상, 엄격한 규제 요건에 의해 주도되고 있습니다. 분산되고 적응성이 높은 임상시험 설계는 환자 직접 물류 및 적시 재고 관리와 같은 전문 공급망 솔루션에 대한 수요를 촉진하고 있습니다. 생물학적 제제 및 세포-유전자 치료제 임상시험 증가로 온도 관리된 보관 및 배송이 필요하며, IoT 기반 추적 및 AI 기반 수요 예측과 같은 디지털화는 공급망 효율을 최적화하고 있습니다.

서비스별로는 물류 및 유통, 보관 및 보관, 포장, 라벨링, 블라인딩, 제조, 비교기 조달, 기타 서비스로 구분되며, 2024년에는 물류 및 유통 서비스가 시장을 장악하고 임상시험 프로토콜의 복잡성 증가, 임상연구의 세계화, 비용 효율적인 공급망 관리에 대한 수요 증가로 인해 조달 및 구매 서비스가 높은 CAGR을 나타낼 것으로 예상됩니다. 공급망 관리에 대한 수요 증가로 인해 조달 및 구매 서비스가 더 높은 CAGR로 성장할 것으로 예상됩니다. 스폰서 및 CRO는 규제 준수, 공급 위험 감소, 재고 관리 최적화를 위해 전문 공급업체에 조달을 아웃소싱하고 있습니다.

단계별 부문은 다시 I상, II상, III상, IV상, BA/BE 단계로 나뉩니다. 생물학적 제제, 세포 및 유전자 치료, 개인 맞춤형 의료의 부상으로 인해 임상 3상 시험에서 특수 보관 및 운송 솔루션에 대한 수요가 더욱 증가하고 있습니다. 생물학적 제제, 유전자 치료제, 표적치료제 등 혁신적인 치료법에 대한 관심이 높아짐에 따라 임상시험 약물의 효능과 최적 용량을 평가하는 임상 2상 시험이 급증하고 있기 때문입니다.

최종 사용자별로 시장은 제약 및 생명공학 기업, CRO 및 CDMO, 기타로 구분되며, 2024년에는 제약 및 생명공학 기업이 이 부문을 지배할 것으로 예상됩니다. R&D 파이프라인의 지속적인 확장, 혁신적인 치료법에 대한 투자 증가, 임상시험의 세계화로 인해 제약 및 생명공학 기업은 여전히 임상시험용 의약품의 가장 큰 소비자로 시장에서의 우위를 강화하고 있습니다. 또한 CRO와 CDMO는 AI를 활용한 공급망 최적화, 추적성을 위한 블록체인, 효율성과 컴플라이언스 강화를 위한 실시간 재고 관리 등 디지털 기술을 통합하여 역량을 확장하고 있습니다.

지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 구분됩니다. 북미는 2024년 임상시험 용품 시장을 장악하고 예측 기간 동안 계속 지배할 것으로 예상됩니다. 미국이 북미 시장을 주도하고 있지만, 이는 주요 학술 연구 기관의 존재와 생명공학에 대한 막대한 투자에 기인합니다. 분산형 임상시험, 첨단 콜드체인 물류, DTP(direct-to-patient) 전달 모델의 채택이 증가하면서 미국 시장이 더욱 강화되고 있습니다. 또한, 잘 구축된 임상시험 인프라, 선진화된 의료 시스템, 의약품 개발을 위한 강력한 정부 자금 지원 등이 미국의 선도적 지위에 기여하고 있습니다. 생물학적 제제, 바이오시밀러, 첨단 치료제에 대한 수요가 증가함에 따라 전문적인 공급망 서비스, 콜드체인 물류, 규제에 부합하는 유통망의 필요성이 증가하고 있습니다. 헬스케어 인프라의 지속적인 개선, 유리한 정부 정책, 아웃소싱 추세의 확대로 인해 아시아태평양은 향후 몇 년동안 임상시험 용품 시장에서 강력한 성장을 이룰 것으로 예상됩니다.

세계의 임상시험 용품 시장에 대해 조사했으며, 서비스별, 단계별/유형별/치료 분야별/지역별 동향, 시장 진출기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 프리미엄 인사이트

제5장 시장 개요

• 서론
• 시장 역학
• 고객의 비즈니스에 영향을 미치는 동향/혼란
• 밸류체인 분석
• 생태계 분석
• 가격 분석
• 투자와 자금조달 시나리오
• 기술 분석
• 2025-2026년 주요 컨퍼런스 및 이벤트
• 규제 상황
• Porter의 Five Forces 분석
• 주요 이해관계자와 구입 기준
• AI/생성형 AI가 임상시험 용품 시장에 미치는 영향

제6장 임상시험 용품 시장(서비스별)

• 서론
• 물류 및 유통 서비스
• 콤퍼레이터 조달 서비스
• 포장, 라벨링 및 블라인드 가공 서비스
• 제조 서비스
• 보관 및 보존 서비스
• 기타

제7장 임상시험 용품 시장(Phase별)

• 서론
• PHASE III
• PHASE II
• PHASE I
• PHASE IV
• PHASE BA/BE

제8장 임상시험 용품 시장(유형별)

• 서론
• 저분자
• 생물제제
• 의료기기

제9장 임상시험 용품 시장(치료 분야별)

• 서론
• 종양과
• 신경과
• 호흡기질환
• 대사질환/내분비과
• 심혈관계 질환
• 피부과
• 소화기과
• 면역 질환
• 감염증
• 정신과
• 안과
• 혈액과
• 비뇨생식기 및 부인과
• 기타

제10장 임상시험 용품 시장(지역별)

• 서론
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시경제 전망
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 스위스
  • 네덜란드
  • 기타
• 아시아태평양
  • 아시아태평양의 거시경제 전망
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 싱가포르
  • 기타
• 라틴아메리카
  • 라틴아메리카의 거시경제 전망
  • 브라질
  • 멕시코
  • 기타
• 중동
  • 중동의 거시경제 전망
  • GCC 국가
  • 기타
• 아프리카
  • 아웃소싱 서비스 수요 증가가 시장 성장을 가속
  • 아프리카의 거시경제 전망

제11장 경쟁 구도

• 서론
• 주요 시장 진출기업의 전략/강점
• 매출 분석, 2020년-2024년
• 시장 점유율 분석, 2024년
• 기업 평가 매트릭스 : 주요 시장 진출기업, 2024년
• 기업 평가 매트릭스 : 스타트업/중소기업, 2024년
• 기업 평가와 재무 지표
• 브랜드/서비스 비교
• 경쟁 시나리오

제12장 기업 개요

• 주요 시장 진출기업
  • THERMO FISHER SCIENTIFIC INC.
  • NOVO HOLDINGS A/S
  • UNITED PARCEL SERVICE OF AMERICA, INC.
  • EUROFINS SCIENTIFIC
  • PIRAMAL PHARMA LIMITED
  • IQVIA
  • ICON PLC
  • LONZA
  • UNIPHAR GROUP PLC
  • ALMAC GROUP
  • SHARP SERVICES, LLC
  • PCI PHARMA SERVICES
  • PAREXEL INTERNATIONAL(MA) CORPORATION
  • BIOCAIR
• 기타 기업
  • CENCORA, INC.
  • CLINIGEN LIMITED
  • KLIFO
  • IPS PHARMA
  • COREX LOGISTICS LIMITED
  • OCT GROUP LLC
  • MYONEX
  • INCEPTUA GROUP
  • ANCILLARE, LP
  • ADALLEN PHARMA
  • CLINICAL SERVICES INTERNATIONAL(CSI)
  • NUVISAN GMBH
  • AENOVA HOLDING GMBH

제13장 부록

영문목차

The global Clinical Trial Supplies market is anticipated to reach USD 8.18 billion in 2030 from USD 5.34 billion in 2025, with a significant CAGR of 8.9%. The clinical trial supplies market is driven by the increasing volume and complexity of global clinical trials, the rise of personalized medicine, and stringent regulatory requirements. Decentralized and adaptive trial designs are fueling demand for specialized supply chain solutions, including direct-to-patient logistics and just-in-time inventory management. Growing biologics and cell & gene therapy trials necessitate temperature-controlled storage and distribution. Digitalization, such as IoT-enabled tracking and AI-driven demand forecasting, is optimizing supply chain efficiency.

"Logistics & Distribution Services dominated the service segment"

Based on services the market is segmented into Logistics & distribution, storage & retention, packaging, labeling and blinding, manufacturing, comparator sourcing and other services. Logistics & Distribution Services dominated the market in 2024 and Sourcing & Procurement Services is anticipated to grow at higher CAGR owing to increasing complexity of trial protocols, the globalization of clinical studies, and the rising demand for cost-effective supply chain management. Sponsors and CROs are outsourcing procurement to specialized vendors to ensure regulatory compliance, mitigate supply risks, and optimize inventory management.

"Phase III segment dominate the phase segment in 2024"

The phase segment is further divided into Phase I, Phase II, Phase III, Phase IV and Phase BA/BE. The rise of biologics, cell & gene therapies, and personalized medicine has further intensified the demand for specialized storage and transportation solutions in Phase III trials. The Phase II segment is anticipated to grow at a significant CAGR during the forecast period in the Clinical Trial Supplies Market owing to the rising focus on innovative therapies, including biologics, gene therapies, and targeted drugs, has led to a surge in Phase II trials, which assess the efficacy and optimal dosing of investigational treatments.

"Pharmaceutical & Biotechnology Companies dominated the segment"

Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, CROs & CDMOs and others. Pharmaceutical & biotechnology companies dominated the segment in 2024. With the continuous expansion of R&D pipelines, increased investments in innovative therapies, and the globalization of clinical trials, pharmaceutical and biotechnology companies remain the largest consumers of clinical trial supplies, reinforcing their dominance in the market. Additionally, CROs and CDMOs are expanding their capabilities by integrating digital technologies such as AI-driven supply chain optimization, blockchain for traceability, and real-time inventory management to enhance efficiency and compliance.

"North America: the largest share of the Clinical Trial Supplies market"

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the Clinical Trial Supplies market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of leading academic & research institutions, and significant investment in biotechnology. The growing adoption of decentralized trials, advanced cold chain logistics, and direct-to-patient (DTP) delivery models has further strengthened the U.S. market. Moreover, the presence of a well-established clinical trial infrastructure, advanced healthcare system, and strong government funding for drug development has contributed to the country's leading position. The increasing demand for biologics, biosimilars, and advanced therapies is driving the need for specialized supply chain services, cold chain logistics, and regulatory-compliant distribution networks. With continuous improvements in healthcare infrastructure, favorable government policies, and growing outsourcing trends, APAC is expected to experience robust growth in the clinical trial supplies market in the coming years.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the Clinical Trial Supplies market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

The prominent players operating in the Clinical Trial Supplies market are Almac Group (UK), Novo Holdings A/S (Denmark), Marken (UPS) (US), PCI Pharma Services (US), Sharp Services LLC (US), Thermo Fisher Scientific Inc. (US), Cencora, Inc. (US), Myonex (US), Clinigen Limited (UK), Inceptua Group (Luxembourg), Eurofins Scientific (Luxembourg), Paraxel International Corporation (US), ICON Plc (Ireland), IQVIA (US), Nuvissan GmbH (Germany), Aenova Holding GmbH (Germany), Klifo (Denmark), IPS Pharma (UK), Corex Logistic Limited (Ireland), Biocair (US), Piramal Group (India), Lonza (Switzerland), OCT Group LLC (Germany), Ancillare LP (US), N-SIDE (Belgium), Adallen Pharma (UK), Uniphar Group (Ireland), Clinical Services International (UK) and among others.

Research Coverage:

Clinical Trial Supplies market report is segmented based on services (Logistics & Distribution, Storage & Retention, Packaging, Labeling and Blinding{Primary Packaging, Secondary Packaging and Labeling & Binding}, Manufacturing, Comparator Sourcing , and Other Services), Phase ( Phase I, Phase II, Phase III, Phase IV and Phase BA/BE), Type (Small Molecules, Biologics [Monoclonal Antibodies, Vaccines and Others], Medical Devices), Therapeutic Area (Oncology, Neurology, Respiratory Disorder, Metabolic Disorder/Endocrinology, Cardiovascular System Disorders, Dermatology, Gastrointestinal, Immunological Disorder, Infectious Diseases, Psychiatry, Ophthalmology, Haematology, Genitourinary and Women's Health, and Others), End Users (pharmaceutical & biotechnology companies, CROs & CDMOs and others). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the Clinical Trial Supplies market. A detailed analysis of the key industry players has been done to provide insights into their business overview, services, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the Clinical Trial Supplies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the Clinical Trial Supplies and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers ( Increasing Number of Clinical Trials, Technological Advancements in Supply Chain Management), restraints (High Cost of clinical trial supplies), opportunities (Rise of Decentralized & Direct-to-Patient (DTP) Trials) and Challenges ( managing global supply chains) influencing the growth of the market.
• Service Development/Innovation: Detailed insights on upcoming technologies in Clinical Trial Supplies, research and development activities, and new service launches in the Clinical Trial Supplies market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the Clinical Trial Supplies market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players lmac Group (UK), Novo Holdings A/S (Denmark), Marken (UPS) (US), PCI Pharma Services (US), Sharp Services LLC (US), Thermo Fisher Scientific Inc. (US), Cencora, Inc. (US), Myonex (US), Clinigen Limited (UK), Inceptua Group (Luxembourg), Eurofins Scientific (Luxembourg), Paraxel International Corporation (US), ICON Plc (Ireland), IQVIA (US), Nuvissan GmbH (Germany) and among others

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS & REGIONS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY RESEARCH
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL MARKET ESTIMATION
    • 2.2.1.1 Insights from primary experts
  • 2.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW
• 4.2 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE AND COUNTRY (2024)
• 4.3 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY TYPE, 2025 VS. 2030
• 4.4 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growth in clinical trials & drug development
    • 5.2.1.2 Expansion of global and multicenter trials accelerating demand for clinical trial supplies
    • 5.2.1.3 Rising demand for personalized medicine and biologics
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High costs associated with clinical trial supplies
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Rise in decentralized and virtual trials
    • 5.2.3.2 Integration of digital technologies in supply chain management
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Supply chain disruptions and drug shortages
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
  • 5.5.1 CLINICAL TRIAL SUPPLIES MARKET: RAW MATERIAL PROVIDERS
  • 5.5.2 CLINICAL TRIAL SUPPLIES MARKET: SERVICE PROVIDERS
  • 5.5.3 CLINICAL TRIAL SUPPLIES MARKET: END USERS
  • 5.5.4 CLINICAL TRIAL SUPPLIES MARKET: REGULATORY BODIES
• 5.6 PRICING ANALYSIS
  • 5.6.1 AVERAGE SELLING PRICE, BY KEY PLAYER (QUALITATIVE)
  • 5.6.2 INDICATIVE PRICE, BY SERVICE (QUALITATIVE)
• 5.7 INVESTMENT AND FUNDING SCENARIO
• 5.8 TECHNOLOGY ANALYSIS
  • 5.8.1 KEY TECHNOLOGIES
    • 5.8.1.1 Serialization & track-and-trace technologies
    • 5.8.1.2 Interactive response technology (IRT/IVR/IWR)
    • 5.8.1.3 Cold chain & temperature monitoring solutions
  • 5.8.2 COMPLEMENTARY TECHNOLOGIES
    • 5.8.2.1 Artificial intelligence (AI) & machine learning (ML)
    • 5.8.2.2 Blockchain for supply chain transparency
  • 5.8.3 ADJACENT TECHNOLOGIES
    • 5.8.3.1 Cryopreservation & advanced storage technologies
    • 5.8.3.2 Advanced robotics in warehousing & distribution
• 5.9 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.2 REGULATORY FRAMEWORK
    • 5.10.2.1 North America
      • 5.10.2.1.1 US
      • 5.10.2.1.2 Canada
    • 5.10.2.2 Europe
      • 5.10.2.2.1 Germany
      • 5.10.2.2.2 France
      • 5.10.2.2.3 Italy
    • 5.10.2.3 Asia Pacific
      • 5.10.2.3.1 Japan
      • 5.10.2.3.2 China
      • 5.10.2.3.3 India
    • 5.10.2.4 Latin America
      • 5.10.2.4.1 Brazil
    • 5.10.2.5 Middle East & Africa
      • 5.10.2.5.1 GCC Countries
      • 5.10.2.5.2 South Africa
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 THREAT OF NEW ENTRANTS
  • 5.11.2 BARGAINING POWER OF SUPPLIERS
  • 5.11.3 BARGAINING POWER OF BUYERS
  • 5.11.4 THREAT OF SUBSTITUTES
  • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BUYING CRITERIA
• 5.13 IMPACT OF AI/GENERATIVE AI ON CLINICAL TRIAL SUPPLIES MARKET
  • 5.13.1 INTRODUCTION
  • 5.13.2 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL SUPPLIES ECOSYSTEM

6 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE

• 6.1 INTRODUCTION
• 6.2 LOGISTICS & DISTRIBUTION SERVICES
  • 6.2.1 RISING DEMAND DUE TO INCREASING EMPHASIS ON CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH
• 6.3 COMPARATOR SOURCING SERVICES
  • 6.3.1 RISING DEMAND FOR COMPARATOR SOURCING TO DRIVE MARKET
• 6.4 PACKAGING, LABELING, AND BLINDING SERVICES
  • 6.4.1 PRIMARY PACKAGING SERVICES
    • 6.4.1.1 Increasing demand for innovative drug formulations to support market growth
  • 6.4.2 SECONDARY PACKAGING SERVICES
    • 6.4.2.1 Increasing complexity of global clinical trials to propel market
  • 6.4.3 LABELING & BLINDING SERVICES
    • 6.4.3.1 Rising number of randomized and double-blind studies to propel market
• 6.5 MANUFACTURING SERVICES
  • 6.5.1 RISING DEMAND FOR ULTRA-LOW-TEMPERATURE STORAGE TO DRIVE GROWTH
• 6.6 STORAGE & RETENTION SERVICES
  • 6.6.1 RISING DEMAND FOR ULTRA-LOW-TEMPERATURE STORAGE TO DRIVE GROWTH
• 6.7 OTHER SERVICES

7 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE

• 7.1 INTRODUCTION
• 7.2 PHASE III
  • 7.2.1 DEVELOPMENT OF BIOLOGICS AND ADVANCED THERAPIES TO SUPPORT MARKET GROWTH
• 7.3 PHASE II
  • 7.3.1 NEED FOR GREATER EFFICIENCY AND COMPLIANCE IN TRIAL LOGISTICS TO SUPPORT MARKET GROWTH
• 7.4 PHASE I
  • 7.4.1 RISING COMPLEXITY OF INVESTIGATIONAL DRUGS TO DRIVE MARKET GROWTH
• 7.5 PHASE IV
  • 7.5.1 INCREASING FOCUS ON PATIENT-CENTRIC APPROACHES TO DRIVE MARKET GROWTH
• 7.6 PHASE BA/BE
  • 7.6.1 ACCELERATING GENERIC DRUG APPROVALS THROUGH OPTIMIZED BA/BE STUDIES TO SUPPORT MARKET GROWTH

8 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE

• 8.1 INTRODUCTION
• 8.2 SMALL MOLECULES
  • 8.2.1 HIGH VOLUME OF SMALL-MOLECULE CLINICAL TRIALS
• 8.3 BIOLOGICS
  • 8.3.1 MONOCLONAL ANTIBODIES
    • 8.3.1.1 Rising demand for monoclonal antibodies to drive growth
  • 8.3.2 VACCINES
    • 8.3.2.1 Increased focus on development of novel vaccines to drive growth
  • 8.3.3 OTHER BIOLOGICS
• 8.4 MEDICAL DEVICES
  • 8.4.1 RISING DEMAND FOR SPECIALIZED LOGISTICS IN MEDICAL DEVICE CLINICAL TRIALS TO DRIVE MARKET GROWTH

9 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA

• 9.1 INTRODUCTION
• 9.2 ONCOLOGY
  • 9.2.1 RISING DISEASE BURDEN TO SUPPORT MARKET GROWTH
• 9.3 NEUROLOGY
  • 9.3.1 INCREASING R&D INVESTMENT TO SUPPORT MARKET GROWTH
• 9.4 RESPIRATORY DISORDERS
  • 9.4.1 RISING INCIDENCE OF RESPIRATORY DISORDERS TO SUPPORT MARKET GROWTH
• 9.5 METABOLIC DISORDERS/ENDOCRINOLOGY
  • 9.5.1 INCREASING GLOBAL DIABETES POPULATION TO SUPPORT MARKET GROWTH
• 9.6 CARDIOVASCULAR SYSTEM DISORDERS
  • 9.6.1 RISING DEMAND IN CLINICAL DIAGNOSTICS TO PROPEL MARKET GROWTH
• 9.7 DERMATOLOGY
  • 9.7.1 GROWING FOCUS ON DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH
• 9.8 GASTROINTESTINAL SYSTEM DISORDERS
  • 9.8.1 INCREASING INCIDENCE OF LIFESTYLE AND DIETARY RISK FACTORS TO DRIVE DEMAND
• 9.9 IMMUNOLOGICAL DISORDERS
  • 9.9.1 GROWING CLINICAL RESEARCH TO SUPPORT MARKET GROWTH
• 9.10 INFECTIOUS DISEASES
  • 9.10.1 RISING OUTBREAKS OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH
• 9.11 PSYCHIATRY
  • 9.11.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL MARKET GROWTH
• 9.12 OPHTHALMOLOGY
  • 9.12.1 RISING NUMBER OF OPHTHALMIC PIPELINE DRUGS TO AID MARKET GROWTH
• 9.13 HEMATOLOGY
  • 9.13.1 INTEGRATION OF ADVANCED SUPPLY CHAIN TECHNOLOGIES TO FUEL MARKET GROWTH
• 9.14 GENITOURINARY & WOMEN'S HEALTH
  • 9.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET GROWTH
• 9.15 OTHER THERAPEUTIC AREAS

10 CLINICAL TRIAL SUPPLIES MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Robust hospital infrastructure and drug research & development to stimulate growth
  • 10.2.3 CANADA
    • 10.2.3.1 Growing preference of pharmaceutical companies to conduct trials to favor growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Growing focus on reducing approval timelines and high spending by global pharmaceutical players to propel market
  • 10.3.3 UK
    • 10.3.3.1 Expanding tax credits leading to encourage growth
  • 10.3.4 FRANCE
    • 10.3.4.1 Evolving regulatory landscape to stimulate growth
  • 10.3.5 ITALY
    • 10.3.5.1 Increasing number of drug approvals to accelerate growth
  • 10.3.6 SPAIN
    • 10.3.6.1 Favorable clinical trial network in public health system to sustain growth
  • 10.3.7 SWITZERLAND
    • 10.3.7.1 Presence of multinational corporations and small and medium-sized pharmaceutical companies to fuel market
  • 10.3.8 NETHERLANDS
    • 10.3.8.1 Increasing collaborations among pharmaceutical giants to promote growth
  • 10.3.9 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 High proportion of domestic industry-sponsored trials to speed up growth
  • 10.4.3 JAPAN
    • 10.4.3.1 Increasing focus on lowering regulatory timelines to facilitate growth
  • 10.4.4 INDIA
    • 10.4.4.1 Rise in early-phase clinical trials to spur growth
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Increasing research funding to favor growth
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Growing focus on new drug development research to drive market
  • 10.4.7 SINGAPORE
    • 10.4.7.1 Advanced research facilities to intensify growth
  • 10.4.8 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Regulatory improvements to support growth
  • 10.5.3 MEXICO
    • 10.5.3.1 Expanding landscape of clinical trials to boost market
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST
  • 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Saudi Arabia
      • 10.6.2.1.1 Booming investments in research infrastructure and life sciences development to aid growth
    • 10.6.2.2 UAE
      • 10.6.2.2.1 Increasing public-private partnerships and genomic research initiatives to augment growth
    • 10.6.2.3 Rest of GCC Countries
  • 10.6.3 REST OF MIDDLE EAST
• 10.7 AFRICA
  • 10.7.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO DRIVE MARKET GROWTH
  • 10.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET
• 11.3 REVENUE ANALYSIS, 2020-2024
• 11.4 MARKET SHARE ANALYSIS, 2024
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Region footprint
    • 11.5.5.3 Service footprint
    • 11.5.5.4 Type footprint
    • 11.5.5.5 End-user footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 11.6.5.1 Detailed list of key startups/SMEs
    • 11.6.5.2 Competitive benchmarking of key startups/SMEs
• 11.7 COMPANY VALUATION & FINANCIAL METRICS
  • 11.7.1 COMPANY VALUATION
  • 11.7.2 FINANCIAL METRICS
• 11.8 BRAND/SERVICE COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 DEALS
  • 11.9.2 EXPANSIONS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 THERMO FISHER SCIENTIFIC INC.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Services offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Service launches
      • 12.1.1.3.2 Deals
      • 12.1.1.3.3 Expansions
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Right to win
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses & competitive threats
  • 12.1.2 NOVO HOLDINGS A/S
    • 12.1.2.1 Business overview
    • 12.1.2.2 Services offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Deals
      • 12.1.2.3.2 Expansions
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Right to win
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 UNITED PARCEL SERVICE OF AMERICA, INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Services offered
    • 12.1.3.3 MnM view
      • 12.1.3.3.1 Right to win
      • 12.1.3.3.2 Strategic choices
      • 12.1.3.3.3 Weaknesses & competitive threats
  • 12.1.4 EUROFINS SCIENTIFIC
    • 12.1.4.1 Business overview
    • 12.1.4.2 Services offered
    • 12.1.4.3 MnM view
      • 12.1.4.3.1 Right to win
      • 12.1.4.3.2 Strategic choices
      • 12.1.4.3.3 Weaknesses & competitive threats
  • 12.1.5 PIRAMAL PHARMA LIMITED
    • 12.1.5.1 Business overview
    • 12.1.5.2 Services offered
    • 12.1.5.3 MnM view
      • 12.1.5.3.1 Right to win
      • 12.1.5.3.2 Strategic choices
      • 12.1.5.3.3 Weaknesses & competitive threats
  • 12.1.6 IQVIA
    • 12.1.6.1 Business overview
    • 12.1.6.2 Services offered
  • 12.1.7 ICON PLC
    • 12.1.7.1 Business overview
    • 12.1.7.2 Services offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Deals
  • 12.1.8 LONZA
    • 12.1.8.1 Business overview
    • 12.1.8.2 Services offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Deals
  • 12.1.9 UNIPHAR GROUP PLC
    • 12.1.9.1 Business overview
    • 12.1.9.2 Services offered
  • 12.1.10 ALMAC GROUP
    • 12.1.10.1 Business overview
    • 12.1.10.2 Services offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Expansions
  • 12.1.11 SHARP SERVICES, LLC
    • 12.1.11.1 Business overview
    • 12.1.11.2 Services offered
  • 12.1.12 PCI PHARMA SERVICES
    • 12.1.12.1 Business overview
    • 12.1.12.2 Services offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Expansions
  • 12.1.13 PAREXEL INTERNATIONAL (MA) CORPORATION
    • 12.1.13.1 Business overview
    • 12.1.13.2 Services offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Deals
  • 12.1.14 BIOCAIR
    • 12.1.14.1 Business overview
    • 12.1.14.2 Services offered
• 12.2 OTHER PLAYERS
  • 12.2.1 CENCORA, INC.
  • 12.2.2 CLINIGEN LIMITED
  • 12.2.3 KLIFO
  • 12.2.4 IPS PHARMA
  • 12.2.5 COREX LOGISTICS LIMITED
  • 12.2.6 OCT GROUP LLC
  • 12.2.7 MYONEX
  • 12.2.8 INCEPTUA GROUP
  • 12.2.9 ANCILLARE, LP
  • 12.2.10 ADALLEN PHARMA
  • 12.2.11 CLINICAL SERVICES INTERNATIONAL (CSI)
  • 12.2.12 NUVISAN GMBH
  • 12.2.13 AENOVA HOLDING GMBH

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS